Patents by Inventor Adrian Britschgi

Adrian Britschgi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250084055
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: August 15, 2024
    Publication date: March 13, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Publication number: 20240368150
    Abstract: The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using them in the treatment of cancer.
    Type: Application
    Filed: February 10, 2022
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Adrian BRITSCHGI, Roman HUTTER, Holger KUEHNE, Bernd KUHN, Thomas LUEBBERS, Laetitia Janine MARTIN, Barbara Johanna MUELLER, Juergen WICHMANN, Marco BRANDSTAETTER
  • Patent number: 12091397
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: September 17, 2024
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Publication number: 20230192643
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: August 1, 2022
    Publication date: June 22, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Patent number: 11401256
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: August 2, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Publication number: 20200207733
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: March 4, 2020
    Publication date: July 2, 2020
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Publication number: 20170298360
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the estrogen receptor (ER?) negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the Large Tumor Suppressor Kinase (LATS). Also provided are a siRNA decreasing or silencing the expression of the Large Tumor Suppressor Kinase (LATS), and an antibody specifically binding to the Large Tumor Suppressor Kinase (LATS), for use to treat breast cancer of the estrogen receptor (ER?) negative type.
    Type: Application
    Filed: September 23, 2015
    Publication date: October 19, 2017
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed BENTIRES-ALJ, Adrian BRITSCHGI
  • Publication number: 20150224190
    Abstract: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which inhibits the interaction between IL-8 and at least one of its receptors for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: July 3, 2013
    Publication date: August 13, 2015
    Inventors: Mohamed Bentires-Alj, Adrian Britschgi, Thomas Radimerski, Rita Andraos-Rey
  • Publication number: 20140343128
    Abstract: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the JAK2-STAT5 pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: November 14, 2012
    Publication date: November 20, 2014
    Applicant: Novartis AG
    Inventors: Mohamed Bentires-Alj, Adrian Britschgi